Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia

24Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective: Esmolol, an ultra-short-acting β-blocker, is known to attenuate myocardial ischemia-reperfusion injury. The aim of this study was to compare the effects of esmolol and potassium on myocardial metabolism during continuous normothermic retrograde blood cardioplegia. Methods: Forty-one patients operated on for isolated aortic valve stenosis were randomly assigned to continuous coronary infusion with either potassium or esmolol during cardiopulmonary bypass. Myocardial metabolism was assessed by measuring the transmyocardial gradient of oxygen content indexed to left ventricular mass of glucose, lactate, and nitric oxide. To do so, blood samples were simultaneously withdrawn upstream (in the cardioplegia line) and downstream of the myocardium (in the left coronary ostium) 10 and 30 minutes after aortic crossclamping. Results: Although the cardioplegia flow rate and pressure were similar, esmolol markedly reduced the transmyocardial gradient of oxygen content indexed to left ventricular mass compared with potassium: 13 ± 6 vs 20 ± 6 mL of oxygen per liter of blood per 100 g of myocardium, respectively, at 10 minutes and 16 ± 8 vs 24 ± 8 mL of oxygen per liter of blood per 100 g of myocardium, respectively, at 30 minutes (P = .009). Coronary glucose and lactate transmyocardial gradients were similar in both groups, indicating adequate myocardial perfusion in all patients at all times. In addition, during retrograde cardioplegia, esmolol showed a lower nitric oxide release compared with that caused by potassium (39 ± 49 μmol × L-1 for potassium vs 14 ± 8 μmol × L-1 for esmolol at 10 minutes and 39 ± 47 μmol × L-1 for potassium vs 6 ± 8 μmol × L-1 for esmolol at 30 minutes, P = .05). However, hemodynamic parameters and plasma troponin I levels remained unchanged postoperatively between the 2 types of cardioplegia. Conclusion: Esmolol provides potent myocardial protection in hypertrophied hearts, at least in part, by reducing myocardial oxygen metabolism.

Cite

CITATION STYLE

APA

Scorsin, M., Mebazaa, A., Al Attar, N., Medini, B., Callebert, J., Raffoul, R., … Lessana, A. (2003). Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia. Journal of Thoracic and Cardiovascular Surgery, 125(5), 1022–1029. https://doi.org/10.1067/mtc.2003.175

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free